Lisata Therapeutics Inc
lisata.comWhat Do They Do?
Develops certepetide, an investigational drug intended to help other cancer therapies reach solid tumors, for patients with solid tumors.
10-K for FY2024, filed Mar 12, 2026
How Do They Make Money?
Lisata earns money by licensing certepetide: partners may pay upfront fees, development and commercial milestone payments, and royalties on licensed product sales. A distinct license’s nonrefundable upfront fee is earned when the licensee can use and benefit from it.
10-K for FY2024, filed Mar 12, 2026
$200K
-
10-K for FY2024, filed Mar 12, 2026
$200K ↗
Who Are Their Customers?
Lisata pursues licenses and collaborations with drug developers and academic trial sponsors. Qilu held an exclusive license to develop and commercialize certepetide in Greater China.
10-K for FY2024, filed Mar 12, 2026Our investigational drug candidate from the CendR Platform®, certepetide, holds broader potential to be combined as a co-administration…View ↗
Certepetide was also the subject of a Phase 2b trial in first-line mPDAC patients, the ASCEND trial. We collaborated with the academic…View ↗
Previously, Cend (which was subsequently acquired by us) and Qilu entered into the License and Collaboration Agreement, pursuant to which…View ↗
Do Revenues Turn Into Profits?
No. It lost $16.6M in FY2024.
10-K for FY2024, filed Mar 12, 2026
−$18.2MView ↗
10-K for FY2024, filed Mar 12, 2026
−$16.6MView ↗
10-K for FY2024, filed Mar 12, 2026
−$16MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$2.9MView ↗
- ▼ −37% (Loss)
- vs −$4.7M in Q2 FY2025
-
Aug 4, 2026
Lisata reduced its workforce and sued Kuva over the merger agreement
Lisata approved a workforce reduction while pursuing strategic options and sued Kuva, seeking damages for stockholders’ expected benefits from the transaction.
Sources
8-K, filed Aug 4, 2026
On August 3, 2026, the board of directors (the “Board”) of Lisata Therapeutics, Inc. (the “Company”) approved a reduction in workforce by…View ↗
-
Jul 24, 2026
Lisata terminated its merger agreement with Kuva after the tender offer failed
Kuva did not accept tendered shares after failing to obtain sufficient financing; Lisata said Kuva owed a termination fee and planned a strategic-options review.
Sources
8-K, filed Jul 24, 2026
On July 24, 2026, Lisata Therapeutics, Inc. (the “Company”) terminated the previously announced Agreement and Plan of Merger, dated as of…View ↗
From cell therapy to cancer drug development
The older report described cell-based treatments for ischemic diseases, including heart, limb and kidney conditions. The latest report centers on certepetide, intended to help other anti-cancer drugs penetrate solid tumors.
10-K for FY2021, filed Mar 22, 2022 10-K for FY2024, filed Mar 12, 2026Caladrius Biosciences, Inc. (“we,” “us,” “our,” “Caladrius” or the “Company”) is a clinical-stage biopharmaceutical company dedicated to…View ↗
XOWNA® (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow-on Phase 2b study (FREEDOM…View ↗
Our proprietary cell technology using autologous (a patient’s own naturally occurring) CD34+ cells has led to the development of…View ↗
Loading...
